Home  |  Top News  |  Most Popular  |  Video  |  Multimedia  |  News Feeds  |  Feedback
  Medicine  |  Nature & Earth  |  Biology  |  Technology & Engineering  |  Space & Planetary  |  Psychology  |  Physics & Chemistry  |  Economics  |  Archaeology
Top > Medicine, Health Care > Blood Levels of Immune Protein… >
Blood Levels of Immune Protein Predict Risk in Hodgkin Disease

Published: December 10, 2012.
By Dana-Farber Cancer Institute
http://www.dfci.harvard.edu

Blood levels of an immunity-related protein, galectin-1, in patients with newly diagnosed Hodgkin lymphoma reflected the extent of their cancer and correlated with other predictors of outcome, scientists reported at the American Society of Hematology annual meeting.

In a study of 315 patients from a German database, researchers from Dana-Farber Cancer Institute found that serum galectin-1 levels "are significantly associated with tumor burden and additional adverse clinical characteristics in newly diagnosed Hodgkin lymphoma (HL) patients."

The measurements were made possible by a new laboratory test called a "sandwich ELISA" devised by the Dana-Farber team, led by Margaret Shipp, MD, director of the lymphoma program at Dana-Farber. Galectin-1 is a protein which, when overexpressed by Hodgkin lymphoma cells, allows them to evade the body's immune response that normally would detect the cancer and attack it with cell-killing lymphocytes. The Shipp group developed antibodies that recognize the galectin-1 protein and were used in developing the sandwich ELISA assay.

Since the protein is secreted into the bloodstream, the investigators hypothesized that measuring relative levels of galectin-1 in newly diagnosed, untreated Hodgkin patients could help to assess likely outcomes in those patients. Such predictions, in turn, could help physicians decide how aggressively to treat the lymphoma, Shipp explained. With further development, she added, the assay could become "an objective test that might help make decisions on which way to treat patients."

The Dana-Farber scientists collaborated with researchers of the German Hodgkin Study Group (GHSG) at the University Hospital of Cologne. Shipp said that the GHSG has "probably the largest, most comprehensive data on clinical trials of patient with well-defined Hodgkin lymphoma." The 315 patients whose blood levels of galactin-1 were tested in the study had been enrolled in three different clinical trials – one for early-stage disease, a second for early-stage disease with additional less-favorable risk factors, and the third for patients with bulky localized or advanced-stage disease.

Using the sandwich ELISA assay, the Dana-Farber investigators found that blood galectin-1 levels in Hodgkin lymphoma patients were significantly higher than in normal control patients. They also found that relative galectin-1 levels were correlated with the risk factors that had been used to assign the 315 patients to the three different clinical trials. Direct comparisons of the galectin-1 levels with patient outcomes are awaiting the completion of one of the clinical trials, the researchers noted.

Beyond the potential for a clinical test, galectin-1 holds promise as a therapeutic target, said Shipp, whose group has made a "neutralizing" antibody to block the protein. She said the antibody, which is produced in mice, would need to be "humanized," or genetically modified to be compatible with human patients, and then undergo rigorous testing for safety and efficacy. This is under discussion with potential industrial partners, said Shipp.


Show Reference »


Translate this page: Chinese French German Italian Japanese Korean Portuguese Russian Spanish


 
All comments are reviewed before being posted. We cannot accept messages that refer a product, or web site.If you are looking for a response to a question please use our another feedback page.
Related »

Sos 
7/18/11 
NYU Researchers Develop Compound to Block Signaling of Cancer-causing Protein
By New York University
Researchers at New York University's Department of Chemistry and NYU Langone Medical Center have developed a compound that blocks signaling from a protein implicated in many types of cancer. …
Protein 
5/21/10 
Switch Protein Also Influences the Cytoskeleton
By Ruhr-Universitaet-Bochum
The protein Ras is known as the switch for cell division when it is activated. Mutations in Ras and its interaction partners can thus lead to the development of …
Molecules 
10/21/13 
New Idea for Targeting the Common Cancer Protein KRAS
By American Association for Cancer Research
BOSTON — Patients with cancers driven by the protein KRAS, which are particularly hard to treat, may benefit from small molecules that attach to and disrupt the function of …
Mtor 
10/29/11 
Unraveling the Complex Signaling That Helps Cells Know When to Grow, When to Sit Tight
By Beth Israel Deaconess Medical Center
Even yeast understand austerity. A finely tuned system evolved early on to help cells survive in a world where good times come as fast as they go. The system, …
Bone 
2/2/11 
New Gift from Mother Nature’s Medicine Chest May Help Prevent And Treat Bone Diseases
By American Chemical Society
One of Mother Nature's latest gifts to medical science is stirring excitement with the discovery that the substance — obtained from a coral-reef inhabiting cyanobacterium — appears to be …
More » 
 
© Newsline Group  |  About  |  Privacy Policy  |  Feedback  |  Mobile  |  Japanese Edition